Abstract
In two transversal studies (totaling around 400 patients), coffee consumption was associated with a significant or borderline-significant reduction in the fibrosis stage. In a third study (HALT-C, around 1000 patients), dealing only with patients having initially severe fibrosis and not cured by a previous antiviral treatment, the prevalence of cirrhosis was lower in coffee drinkers. Histologic inflammation was reduced in one study, but not in the two other studies, with increasing coffee consumption. Hepatitis C virus load was slightly higher, and aspartate transaminase slightly lower, in coffee drinkers. In patients retreated with peginterferon and ribavirin, virologic responses were higher, and tolerance better, in coffee drinkers. Finally, during a 3.5year follow-up, HALT-C patients drinking coffee had a reduced risk of disease progression.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
